Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.46 |
| ▸ | FDPS | P14324 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.44 |
| ▸ | NNMT | P40261 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
| ▸ | PNMT | P11086 | 1/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17094197 | 0.98 | HDAC8 (0.45) | HDAC8FDPSLOXL2NNMTUSP2 | |
| SCHEMBL17094015 | 0.98 | — | — | |
| SCHEMBL17094018 | 0.98 | — | — | |
| Hydrochloric Acid SCHEMBL17094198 | 0.95 | HDAC8 (0.46) | HDAC8FDPSLOXL2NNMTUSP2 | |
| Hydrochloric Acid SCHEMBL22366435 | 0.93 | HDAC8 (0.45) | HDAC8FDPSLOXL2NNMTUSP2 | |
| Hydrochloric Acid SCHEMBL1977524 | 0.81 | TAAR1 (0.46) | HDAC8FDPSLOXL2NNMTCHRNA7 | |
| SCHEMBL12592962 | 0.80 | TAAR1 (0.50) | HDAC8FDPSLOXL2NNMTUSP2 | |
| Hydrochloric Acid SCHEMBL11421182 | 0.79 | TP53 (0.52) | HDAC8FDPSNNMTUSP2CYP2C19 | |
| Benzylamine SCHEMBL28393765 | 0.78 | LOXL2 (0.58) | LOXL2CYP2C19PNMTENPP2 | |
| SCHEMBL3206603 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3511328-B1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | NOVARTIS AG (CH) | 2021-03-03 | — | — | EP | disclosed |
| US-10369138-B2 | Monobactam organic compounds for the treatment of bacterial infections | NOVARTIS AG (CH) | 2019-08-06 | — | — | US | disclosed |
| US-20190231752-A1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2019-08-01 | — | — | US | disclosed |
| EP-3511328-A1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | Novartis AG (CH) | 2019-07-17 | — | — | EP | disclosed |
| EP-3122745-A1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | Novartis AG (CH) | 2017-02-01 | — | — | EP | disclosed |
| US-20160051523-A1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | NOVARTIS AG (CH) | 2016-02-25 | — | — | US | disclosed |
| US-9174978-B2 | Monobactam organic compounds for the treatment of bacterial infections | NOVARTIS AG (CH) | 2015-11-03 | — | — | US | disclosed |
| WO-2015148379-A1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | NOVARTIS AG (CH) | 2015-10-01 | — | — | WO | disclosed |
| US-20150266867-A1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | NOVARTIS AG (CH) | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266867-A1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MGAM, MGAM2, BPGM | HDAC8 4565/4885FDPS 82/4885LOXL2 1777/4885 |
| US-20190231752-A1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MGAM, MGAM2, BPGM | HDAC8 4565/4885FDPS 82/4885LOXL2 1777/4885 |
| US-10369138-B2 | Monobactam organic compounds for the treatment of bacterial infections | MGAM, MGAM2, BPGM | HDAC8 4565/4885FDPS 82/4885LOXL2 1777/4885 |
| US-20160051523-A1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MGAM, MGAM2, BPGM | HDAC8 4565/4885FDPS 82/4885LOXL2 1777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.